Return to Today's science sparks archives

2013-10-01

Fig 4. Effect of TLR2 activation in in vitro-cultured primary normal BM CD34+ cells. (a) Flow cytometry analysis of normal CD34+ cells after being treated with MALP2 or PAM3CSK4 for 48 h. Compared with control, treatment resulted in a decreased percentage of early erythroid progenitor cells marked with CD71+ and HLA-DR.

Fig 4. Effect of TLR2 activation in in vitro-cultured primary normal BM CD34+ cells. (a) Flow cytometry analysis of normal CD34+ cells after being treated with MALP2 or PAM3CSK4 for 48 h. Compared with control, treatment resulted in a decreased percentage of early erythroid progenitor cells marked with CD71+ and HLA-DR.
  • Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, Neuberg D, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G

  • Leukemia. 2013 Sep;27(9):1832-40.

2013-10-02

Fig 1. Hypotonicity is required for rapid leukocyte recruitment to larval zebrafish tail fin wounds. d) HyPer imaging of wound margin H2O2 production in response to wounding in hypotonic medium (h), isotonic medium (i) or isotonic medium + 100 μM of the NADPH oxidase inhibitor diphenyliodonium chloride (i/DPI).

Fig 1. Hypotonicity is required for rapid leukocyte recruitment to larval zebrafish tail fin wounds. d) HyPer imaging of wound margin H2O2 production in response to wounding in hypotonic medium (h), isotonic medium (i) or isotonic medium + 100 μM of the NADPH oxidase inhibitor diphenyliodonium chloride (i/DPI).
  • Enyedi B, Kala S, Nikolich-Zugich T, Niethammer P

  • Nat Cell Biol. 2013 Sep;15(9):1123-30.

2013-10-03

Fig 1. CONSORT diagram.

Fig 1. CONSORT diagram.
  • Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Hudis CA, Traina TA; on behalf of the Translational Breast Cancer Research Consortium (TBCRC 011)

  • Clin Cancer Res. 2013 Sep 16; 19(19): 5505-5512.

2013-10-04

Fig 2. Hypothetical models of progression from in situ to invasive breast cancer. (B) Progression from DCIS to IBC as an evolutionary bottleneck.

Fig 2. Hypothetical models of progression from in situ to invasive breast cancer. (B) Progression from DCIS to IBC as an evolutionary bottleneck.
  • Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS

  • Mol Oncol. 2013 Oct;7(5):859-69.

2013-10-07

Fig 1. Overall survival (OS) and disease-free survival (DFS) curves according to the level of SNIP1 expression in 83 lung cancer and normal tissues.

Fig 1. Overall survival (OS) and disease-free survival (DFS) curves according to the level of SNIP1 expression in 83 lung cancer and normal tissues.
  • Jeon HS, Choi YY, Fukuoka J, Fujii M, Lyakh LA, Song SH, Travis WD, Park JY, Jen J

  • Lung Cancer. 2013 Oct;82(1):24-30.

2013-10-08

Fig 5. MK-2206 reduces the megakaryocyte burden in a mouse model of PMF. Cells from bone marrows of MPLW515L recipients treated with captisol (vehicle control), 60 mg/kg MK-2206 or 120 mg/kg MK-2206 for 14 days were collected and stained with fluorescently conjugated antibodies against CD41or Mac1/Gr1. (c) Histological sections of the liver after 14 days of treatment.

Fig 5. MK-2206 reduces the megakaryocyte burden in a mouse model of PMF. Cells from bone marrows of MPLW515L recipients treated with captisol (vehicle control), 60 mg/kg MK-2206 or 120 mg/kg MK-2206 for 14 days were collected and stained with fluorescently conjugated antibodies against CD41or Mac1/Gr1. (c) Histological sections of the liver after 14 days of treatment.
  • Khan I, Huang Z, Wen Q, Stankiewicz MJ, Gilles L, Goldenson B, Schultz R, Diebold L, Gurbuxani S, Finke CM, Lasho TL, Koppikar P, Pardanani A, Stein B, Altman JK, Levine RL, Tefferi A, Crispino JD

  • Leukemia. 2013 Sep;27(9):1882-90.

2013-10-09

Fig 2. Sensitivity analyses showing how any future changes in the rate of transplant activity would affect the projected estimates for survivors in the United States by year 2030.

Fig 2. Sensitivity analyses showing how any future changes in the rate of transplant activity would affect the projected estimates for survivors in the United States by year 2030.
  • Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL, Hahn T, Jakubowski A, Joffe S, Lazarus HM, Parsons SK, Robien K, Lee SJ, Kuntz KM

  • Biol Blood Marrow Transplant. 2013 Oct;19(10):1498-501.

2013-10-10

Fig 1. Concordance of TERT promoter and known thyroid driver genes (BRAF, RAS, RET/PTC) in thyroid cancer tumors and cell lines. Each cell represents one sample. Colored and gray shadings denote mutant and wild-type status, respectively. For TERT mutations, darker shading represents homozygous mutations.

Fig 1. Concordance of TERT promoter and known thyroid driver genes (BRAF, RAS, RET/PTC) in thyroid cancer tumors and cell lines. Each cell represents one sample. Colored and gray shadings denote mutant and wild-type status, respectively. For TERT mutations, darker shading represents homozygous mutations.
  • Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA

  • J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6.

2013-10-11

Fig 3. Two-dimensional isodose contours for a single high-dose-rate treatment; dose was prescribed to 7 mm, with mucosal surface limited to 9 Gy.

Fig 3. Two-dimensional isodose contours for a single high-dose-rate treatment; dose was prescribed to 7 mm, with mucosal surface limited to 9 Gy.
  • Folkert MR, Cohen GN, Wu AJ, Gerdes H, Schattner MA, Markowitz AJ, Ludwig E, Ilson DH, Bains MS, Zelefsky MJ, Goodman KA

  • Brachytherapy. 2013 Sep-Oct;12(5):463-70.

2013-10-14

Fig. 1. Sample dosimetric comparison of implant alone to combination therapy. Example of dosimetric comparison of implant alone to combination therapy with EBRT and brachytherapy boost. Blue dashed line: prostate contour; red solid line: 100% isodose line; green solid line: 75% isodose line. Interval spacing between positions of 5 mm. EBRT = external beam radiation therapy.

Fig. 1. Sample dosimetric comparison of implant alone to combination therapy. Example of dosimetric comparison of implant alone to combination therapy with EBRT and brachytherapy boost. Blue dashed line: prostate contour; red solid line: 100% isodose line; green solid line: 75% isodose line. Interval spacing between positions of 5 mm. EBRT = external beam radiation therapy.
  • Spratt DE, Zelefsky MJ

  • Brachytherapy. 2013 Sep-Oct;12(5):389-92.

2013-10-15

Fig 1. Design of gp120 V1V2 domain broadly neutralizing epitope mimics. (A) Crystal structure of a scaffolded V1V2 domain from the CAP45 strain of HIV-1 (red ribbons) in complex with PG9 Fab (gray surface) (PDB ID 3U4E with scaffold hidden). The glycans at N160 and N156 are depicted with colored spheres representing atoms of the mannose (green) and N-acetylglucosamine (blue) residues. Disulfide bonds are shown as yellow sticks. Dashed arrows indicate where the disordered region of the V2 loop would be connected.

Fig 1. Design of gp120 V1V2 domain broadly neutralizing epitope mimics. (A) Crystal structure of a scaffolded V1V2 domain from the CAP45 strain of HIV-1 (red ribbons) in complex with PG9 Fab (gray surface) (PDB ID 3U4E with scaffold hidden). The glycans at N160 and N156 are depicted with colored spheres representing atoms of the mannose (green) and N-acetylglucosamine (blue) residues. Disulfide bonds are shown as yellow sticks. Dashed arrows indicate where the disordered region of the V2 loop would be connected.
  • Aussedat B, Vohra Y, Park PK, Fernández-Tejada A, Alam SM, Dennison SM, Jaeger FH, Anasti K, Stewart S, Blinn JH, Liao HX, Sodroski JG, Haynes BF, Danishefsky SJ

  • J Am Chem Soc. 2013 Sep 4;135(35):13113-20.

2013-10-16

Fig 1. The conventional PET tracer principle and the development of agents that fluorescently convert the Cerenkov radiation optical decay signal.

Fig 1. The conventional PET tracer principle and the development of agents that fluorescently convert the Cerenkov radiation optical decay signal.
  • Thorek DL, Ogirala A, Beattie BJ, Grimm J

  • Nat Med. 2013 Oct;19(10):1345-1350.

2013-10-17

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram displaying the search and selection process of eligible trials.

Fig 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram displaying the search and selection process of eligible trials.
  • Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, Burmeister B, Kelsen D, Niedzwiecki D, Schuhmacher C, Urba S, van de Velde C, Walsh TN, Ychou M, Jensen K

  • Eur J Cancer. 2013 Oct;49(15):3149-58.

2013-10-18

Fig 7. Case 1. Histology and immunohistochemical stains. a H&E image demonstrates the lobulated appearance of the lesion (magnification, 40×). b Higher magnification H&E image of the same specimen shows epithelioid cells in a myxochondroid matrix. (magnification, 200×). c Immunohistochemical stain for S-100 shows diffuse positivity. d Immunohistochemical test for brachyury shows the characteristic nuclear positivity.

Fig 7. Case 1. Histology and immunohistochemical stains. a H&E image demonstrates the lobulated appearance of the lesion (magnification, 40×). b Higher magnification H&E image of the same specimen shows epithelioid cells in a myxochondroid matrix. (magnification, 200×). c Immunohistochemical stain for S-100 shows diffuse positivity. d Immunohistochemical test for brachyury shows the characteristic nuclear positivity.
  • Lantos JE, Agaram NP, Healey JH, Hwang S

  • Skeletal Radiol. 2013 Oct;42(10):1451-9.

2013-10-21

Figure 3. Location of the breakpoint sequences of the deletion in the KLK15 gene.

Figure 3. Location of the breakpoint sequences of the deletion in the KLK15 gene.
  • Lindahl P, Säll T, Bjartell A, Johansson AM, Lilja H, Halldén C

  • PLoS One. 2013 Jul 22;8(7):e69097.
Open Access button

2013-10-22

Fig 4. Human HCC samples display cytoplasmic localization of p16.

Fig 4. Human HCC samples display cytoplasmic localization of p16.
  • Chen YW, Chu HC, Ze-Shiang Lin, Shiah WJ, Chou CP, Klimstra DS, Lewis BC

  • PLoS One. 2013 Jul 24;8(7):e69389.
Open Access button

2013-10-23

Fig 6. Osteoprotegerin secretion by GCT stromal cells was altered selectively by exposure to osteogenic media, BMP2, or SB415286.

Fig 6. Osteoprotegerin secretion by GCT stromal cells was altered selectively by exposure to osteogenic media, BMP2, or SB415286.
  • Steensma MR, Tyler WK, Shaber AG, Goldring SR, Ross FP, Williams BO, Healey JH, Purdue PE

  • PLoS One. 2013 Jul 26;8(7):e69101.
Open Access button

2013-10-24

Fig 1. Representative qualitative retinal oximetry images of retinas from 3 irradiated (A–C) and 3 unirradiated (D–F) subjects from the two cohorts.

Fig 1. Representative qualitative retinal oximetry images of retinas from 3 irradiated (A–C) and 3 unirradiated (D–F) subjects from the two cohorts.
  • Higginson DS, Sahgal A, Lawrence MV, Moyer S, Stefanescu M, Willson AK, Qaqish B, Zanation A, Marks LB, Garg S, Chera BS

  • PLoS One. 2013 Aug 6;8(8):e69657.
Open Access button

2013-10-25

Fig 1. Schematic of 48-well plates connected to the piezo ceramic element.

Fig 1. Schematic of 48-well plates connected to the piezo ceramic element.
  • Loike JD, Plitt A, Kothari K, Zumeris J, Budhu S, Kavalus K, Ray Y, Jacob H

  • PLoS One. 2013 Aug 6;8(8):e68334.
Open Access button

2013-10-28

Fig 1. Kaplan-Meier ocular event-free survival curve of all eyes.

Fig 1. Kaplan-Meier ocular event-free survival curve of all eyes.
  • Francis JH, Barker CA, Wolden SL, McCormick B, Segal K, Cohen G, Gobin YP, Marr BP, Brodie SE, Dunkel IJ, Abramson DH

  • Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):517-23.

2013-10-29

Fig 2. Hypothetical models of progression from in situ to invasive breast cancer. (B) Progression from DCIS to IBC as an evolutionary bottleneck.

Fig 2. Hypothetical models of progression from in situ to invasive breast cancer. (B) Progression from DCIS to IBC as an evolutionary bottleneck.
  • Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, Reis-Filho JS

  • Mol Oncol. 2013 Oct;7(5):859-69.

2013-10-30

Fig 1. Conceptual groupings of S2P mediated signaling pathways.

Fig 1. Conceptual groupings of S2P mediated signaling pathways.
  • Schneider JS, Glickman MS

  • Biochim Biophys Acta. 2013 Dec;1828(12):2808-14.

2013-10-31

This dermatofibroma, hemosiderotic variant displays a diffuse homogeneous bluish pigmentation.

This dermatofibroma, hemosiderotic variant displays a diffuse homogeneous bluish pigmentation.
  • Longo C, Scope A, Lallas A, Zalaudek I, Moscarella E, Gardini S, Argenziano G, Pellacani G

  • Dermatol Clin. 2013 Oct;31(4):637-47.

2013-11-01

Fig 1. Prospective Strategies for Employing Cerebral Organoid Cultures.

Fig 1. Prospective Strategies for Employing Cerebral Organoid Cultures.
  • Chambers SM, Tchieu J, Studer L

  • Cell Stem Cell. 2013 Oct 3;13(4):377-8.

2013-11-04

Fig 2. MIR143-NOTCH1 gene fusion in a benign glomus tumor of the neck soft tissue (GT2). A: Typical morphologic appearance of a glomus tumor with uniform cuboidal cells with pale eosinophilic cytoplasm and round, bland nuclei, with a distinctive angiocentric growth around small blood vessels (H&E, 200×).

Fig 2. MIR143-NOTCH1 gene fusion in a benign glomus tumor of the neck soft tissue (GT2). A: Typical morphologic appearance of a glomus tumor with uniform cuboidal cells with pale eosinophilic cytoplasm and round, bland nuclei, with a distinctive angiocentric growth around small blood vessels (H&E, 200×).
  • Mosquera JM, Sboner A, Zhang L, Chen CL, Sung YS, Chen HW, Agaram NP, Briskin D, Basha BM, Singer S, Rubin MA, Tuschl T, Antonescu CR

  • Genes Chromosomes Cancer. 2013 Nov;52(11):1075-87.

2013-11-05

Fig 4. Correlation between pS6(240/4) inhibition and clinical response to BYL719 in breast cancer patients. (A) Representative sections stained by IHC for pS6(240/4) in paired biopsies obtained from tumors of patients before (untreated) and at day 28 of BYL719 treatment. Patient numbers are indicated at left in parentheses. Images were captured at ×40 magnification; scale bar, 100 μm.

Fig 4. Correlation between pS6(240/4) inhibition and clinical response to BYL719 in breast cancer patients. (A) Representative sections stained by IHC for pS6(240/4) in paired biopsies obtained from tumors of patients before (untreated) and at day 28 of BYL719 treatment. Patient numbers are indicated at left in parentheses. Images were captured at ×40 magnification; scale bar, 100 μm.
  • Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, Tao J, Campos AB, Rodon J, Ibrahim YH, Serra V, Rodrik-Outmezguine V, Hazra S, Singh S, Kim P, Quadt C, Liu M, Huang A, Rosen N, Engelman JA, Scaltriti M, Baselga J

  • Sci Transl Med. 2013 Jul 31;5(196):196ra99.

2013-11-06

Fig 2. Local failure rates for all parameningeal rhabdomyosarcoma patients regardless of intracranial extension between the Intergroup Rhabdomyosarcoma Study (IRS-IV) and Children's Oncology Group (D9803) groups. Local failure rate for patients enrolled on IRS-IV (dashed line) or D9803 (solid line).

Fig 2. Local failure rates for all parameningeal rhabdomyosarcoma patients regardless of intracranial extension between the Intergroup Rhabdomyosarcoma Study (IRS-IV) and Children's Oncology Group (D9803) groups. Local failure rate for patients enrolled on IRS-IV (dashed line) or D9803 (solid line).
  • Spalding AC, Hawkins DS, Donaldson SS, Anderson JR, Lyden E, Laurie F, Wolden SL, Arndt CA, Michalski JM

  • Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):512-6.

2013-11-07

Fig 1. Immunohistochemistry detection of eukaryotic protein synthesis initiation factor 4E (eIF4E) in tumor and in histologically negative margins in 4 resected head and neck squamous cell cancer specimens. Tonsil squamous cell cancer (SCC) eIF4E in tumor (A).

Fig 1. Immunohistochemistry detection of eukaryotic protein synthesis initiation factor 4E (eIF4E) in tumor and in histologically negative margins in 4 resected head and neck squamous cell cancer specimens. Tonsil squamous cell cancer (SCC) eIF4E in tumor (A).
  • Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, Shen R, Korte S, Lisa D, Ganly I, Patel S, Wong RJ, Shaha A, Shah J, Haque S, Katabi N, Pfister DG

  • Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):479-86.

2013-11-08

Fig 2. Decrease in size of pancreatic head mass with IV irinotecan and cetuximab from July 2008 (A) to November 2008 (B).

Fig 2. Decrease in size of pancreatic head mass with IV irinotecan and cetuximab from July 2008 (A) to November 2008 (B).
  • Ang C, Herran LA, Lagunes DR, Klimstra DS, Kemeny NE

  • Tumori. 2013 Mar-Apr;99(2):e61-4.

2013-11-11

Fig 3. Histologic image. Melanoma arising in association with a congenital melanocytic nevus (arrow points to the area of melanoma). Superficial spreading melanoma arising in association with an intradermal nevus.

Fig 3. Histologic image. Melanoma arising in association with a congenital melanocytic nevus (arrow points to the area of melanoma). Superficial spreading melanoma arising in association with an intradermal nevus.
  • Yagerman S, Marghoob AA

  • J Am Acad Dermatol. 2013 Nov;69(5):e227-8.

2013-11-12

Fig 1. Overview of normal hematopoiesis and leukemogenesis. At disease inception, an unknown number of leukemic stem cells (LSCs) may cycle between proliferative and quiescent states. Some proliferating LSCs differentiate into EPCs that retain proliferative capacity but lack long-term self-renewal capacity. After a number of cell-division cycles, the EPCs become late progenitor cells, which eventually mature into leukemic cells that enter circulation [54] and [57].

Fig 1. Overview of normal hematopoiesis and leukemogenesis. At disease inception, an unknown number of leukemic stem cells (LSCs) may cycle between proliferative and quiescent states. Some proliferating LSCs differentiate into EPCs that retain proliferative capacity but lack long-term self-renewal capacity. After a number of cell-division cycles, the EPCs become late progenitor cells, which eventually mature into leukemic cells that enter circulation [54] and [57].
  • Mauro MJ

  • Leuk Res. 2013 Nov;37(11):1395-403.

2013-11-13

Fig 1a. Decision curve comparing the net benefit of models predicting risk of potentially aggressive disease features (non–organ-confined disease, tumor volume >0.5 cm3, or Gleason grade >3) on radical prostatectomy.

Fig 1a. Decision curve comparing the net benefit of models predicting risk of potentially aggressive disease features (non–organ-confined disease, tumor volume >0.5 cm3, or Gleason grade >3) on radical prostatectomy.
  • Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, Vickers A, Lilja H, Roobol MJ

  • Eur Urol. 2013 Nov;64(5):693-9.

2013-11-14

Fig 1. Selection process for studies included in meta-analysis.

Fig 1. Selection process for studies included in meta-analysis.
  • Ensslin CJ, Rosen AC, Wu S, Lacouture ME

  • J Am Acad Dermatol. 2013 Nov;69(5):708-20.

2013-11-15

Fig 7. Proposed model for PrE formation.

Fig 7. Proposed model for PrE formation.
  • Saiz N, Grabarek JB, Sabherwal N, Papalopulu N, Plusa B

  • Development. 2013 Nov;140(21):4311-22.
Open Access button

2013-11-18

Fig 1. Kaplan–Meier estimates of over-all survival between groups.

Fig 1. Kaplan–Meier estimates of over-all survival between groups.
  • Altaf S, Enders F, Jeavons E, Krailo M, Barkauskas DA, Meyers P, Arndt C

  • Pediatr Blood Cancer. 2013 Dec;60(12):2042-6.

2013-11-19

Fig 3. Forkhead box (Fox)o-dependent program in T regulatory (Treg) cells.

Fig 3. Forkhead box (Fox)o-dependent program in T regulatory (Treg) cells.
  • Luo CT, Li MO

  • Trends Immunol. 2013 Nov;34(11):531-9.

2013-11-20

Fig 3. Classification and regression tree results using the following variables: age, stage, tumor subtype, grade (G), myometrial invasion (Myo Inv), total lymph nodes removed, and evaluation of para-aortic lymph nodes. Complexity parameter (CP) = 0.022 for the green highlighted tree; CP = 0.0071 for the tree shown. The numerators indicate number of deaths, and the denominators indicate total number of cases in the subcategory.

Fig 3. Classification and regression tree results using the following variables: age, stage, tumor subtype, grade (G), myometrial invasion (Myo Inv), total lymph nodes removed, and evaluation of para-aortic lymph nodes. Complexity parameter (CP) = 0.022 for the green highlighted tree; CP = 0.0071 for the tree shown. The numerators indicate number of deaths, and the denominators indicate total number of cases in the subcategory.
  • Barlin JN, Zhou Q, St Clair CM, Iasonos A, Soslow RA, Alektiar KM, Hensley ML, Leitao MM Jr, Barakat RR, Abu-Rustum NR

  • Gynecol Oncol. 2013 Sep;130(3):452-6.

2013-11-21

The Taspase1-Mediated Cleavage of MLL1 and MLL2 Is Not Required for Spermatogenesis

The Taspase1-Mediated Cleavage of MLL1 and MLL2 Is Not Required for Spermatogenesis
  • Oyama T, Sasagawa S, Takeda S, Hess RA, Lieberman PM, Cheng EH, Hsieh JJ

  • Dev Cell. 2013 Oct 28;27(2):188-200.

2013-11-22

Models of LSC response to imatinib.

Models of LSC response to imatinib.
  • Mauro MJ

  • Leuk Res. 2013 Nov;37(11):1395-403.

2013-11-25

Transcriptional control of regulatory T (Treg) cell function. (A) Forkhead box P3 (Foxp3), the Treg lineage-specifying factor, is essential for the maintenance of Treg cell suppressive function.

Transcriptional control of regulatory T (Treg) cell function. (A) Forkhead box P3 (Foxp3), the Treg lineage-specifying factor, is essential for the maintenance of Treg cell suppressive function.
  • Luo CT, Li MO

  • Trends Immunol. 2013 Nov;34(11):531-9.

2013-11-26

Fig 4. Invasive mucinous adenocarcinoma demonstrates lepidic and acinar growth. The tumor consists of columnar cells filled with abundant mucin in the apical cytoplasm and shows small basal oriented nuclei (Hematoxylin and eosin 200×).

Fig 4. Invasive mucinous adenocarcinoma demonstrates lepidic and acinar growth. The tumor consists of columnar cells filled with abundant mucin in the apical cytoplasm and shows small basal oriented nuclei (Hematoxylin and eosin 200×).
  • Van Schil PE, Sihoe AD, Travis WD

  • J Surg Oncol. 2013 Oct;108(5):320-6.

2013-11-27

Joint mixed-effects and time-to-dropout modelling of symptomatic improvement in FACT-P total score.

Joint mixed-effects and time-to-dropout modelling of symptomatic improvement in FACT-P total score.
  • Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI

  • Eur J Cancer. 2013 Nov;49(17):3648-57.

2013-11-29

Fig 8. Characterization of a mutant strain deleted of yejK. A and B, MG1655 (panel A) and MG1655ΔyejK (panel B) cells were grown in LB medium at 37 °C for 2 h, fixed, stained with DAPI (a DNA stain, blue channel) and FM 4-64 FX (a live membrane stain, red channel), and imaged by fluorescence microscopy.

Fig 8. Characterization of a mutant strain deleted of yejK. A and B, MG1655 (panel A) and MG1655ΔyejK (panel B) cells were grown in LB medium at 37 °C for 2 h, fixed, stained with DAPI (a DNA stain, blue channel) and FM 4-64 FX (a live membrane stain, red channel), and imaged by fluorescence microscopy.
  • Lee C, Marians KJ

  • J Biol Chem. 2013 Nov 1;288(44):31503-16.

2013-12-02

Figure 4. Correlations between CDH1 and ZEB1 with each member of miR-200 family of miRNAs among samples.

Figure 4. Correlations between CDH1 and ZEB1 with each member of miR-200 family of miRNAs among samples.
  • Romero-Pérez L, López-García MÁ, Díaz-Martín J, Biscuola M, Castilla MÁ, Tafe LJ, Garg K, Oliva E, Matias-Guiu X, Soslow RA, Palacios J

  • Mod Pathol. 2013 Nov;26(11):1514-24.

2013-12-03

Fig 3.Sequence-Specific Recognition of RNA Containing UACAU RNA Recognition Element by B. subtilis MazF. (B) Panels showing the recognition of individual nucleotides in RNA by MazF. Intermolecular hydrogen bonds are indicated by dashed black lines. For clarity, only one nucleotide is shown in yellow in each panel.

Fig 3.Sequence-Specific Recognition of RNA Containing UACAU RNA Recognition Element by B. subtilis MazF. (B) Panels showing the recognition of individual nucleotides in RNA by MazF. Intermolecular hydrogen bonds are indicated by dashed black lines. For clarity, only one nucleotide is shown in yellow in each panel.
  • Simanshu DK, Yamaguchi Y, Park JH, Inouye M, Patel DJ

  • Mol Cell. 2013 Nov 7;52(3):447-58.

2013-12-04

Fig 2. The incremental explained variation is plotted against the distance metric for every possible two-class configuration of the 16 distinct permutations of the four binary markers, excluding only configurations in which one subtype contains fewer than 5% of the cases (green dots). The red dots represent local maxima obtained from k-means clustering. The blue dot corresponds to the classification ER+ versus ER-.

Fig 2. The incremental explained variation is plotted against the distance metric for every possible two-class configuration of the 16 distinct permutations of the four binary markers, excluding only configurations in which one subtype contains fewer than 5% of the cases (green dots). The red dots represent local maxima obtained from k-means clustering. The blue dot corresponds to the classification ER+ versus ER-.
  • Begg CB, Zabor EC, Bernstein JL, Bernstein L, Press MF, Seshan VE

  • Stat Med. 2013 Dec 20;32(29):5039-52.

2013-12-05

Fig 5. In patient 2, fused images obtained at ~1 h show mild 68Ga-DOTA-F(ab')2-trastuzumab uptake in a lung metastasis.

Fig 5. In patient 2, fused images obtained at ~1 h show mild 68Ga-DOTA-F(ab')2-trastuzumab uptake in a lung metastasis.
  • Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, Lu Y, O'Donoghue J, Lyashchenko SK, Carrasquillo JA, Larson SM, Akhurst TJ

  • Nucl Med Commun. 2013 Dec;34(12):1157-65.

2013-12-06

Fig 4. The Mre11 Complex Induces an Oncogene-Driven G2 Arrest. (A) Representative confocal z slices of DAPI-stained (Ai) pHH3-S10 and (Aii) H3K9me3 IF in WT + NeuT mammary glands. Scale bar = 10 μm. Lower panels depict linescan plots for the indicated lines in (Ai) and (Aii).

Fig 4. The Mre11 Complex Induces an Oncogene-Driven G2 Arrest. (A) Representative confocal z slices of DAPI-stained (Ai) pHH3-S10 and (Aii) H3K9me3 IF in WT + NeuT mammary glands. Scale bar = 10 μm. Lower panels depict linescan plots for the indicated lines in (Ai) and (Aii).
  • Gupta GP, Vanness K, Barlas A, Manova-Todorova KO, Wen YH, Petrini JH

  • Mol Cell. 2013 Nov 7;52(3):353-65.

2013-12-09

Fig 3. High-dose-rate brachytherapy planning image; catheter trajectories shown with critical structures including GTV, CTV, and cord indicated. GTV = gross tumor volume; CTV = clinical target volume.

Fig 3. High-dose-rate brachytherapy planning image; catheter trajectories shown with critical structures including GTV, CTV, and cord indicated. GTV = gross tumor volume; CTV = clinical target volume.
  • Folkert MR, Bilsky MH, Cohen GN, Zaider M, Lis E, Krol G, Laufer I, Yamada Y

  • Brachytherapy. 2013 Sep-Oct;12(5):449-56.

2013-12-10

Fig 1. Illustration of the average enzyme principle for a linear metabolic pathway.

Fig 1. Illustration of the average enzyme principle for a linear metabolic pathway.
  • Reznik E, Chaudhary O, Segrè D

  • FEBS Lett. 2013 Sep 2;587(17):2891-4.

2013-12-11

Fig 2. Flowchart of the robust optimization approach. (a) Replica based robust optimization. (b) Evaluation of the robust and PTV optimized plans.

Fig 2. Flowchart of the robust optimization approach. (a) Replica based robust optimization. (b) Evaluation of the robust and PTV optimized plans.
  • Zhang P, Hunt M, Happersett L, Yang J, Zelefsky M, Mageras G

  • Phys Med Biol. 2013 Nov 7;58(21):7803-13.

2013-12-12

Fig 1. magoo mutant cortex has reduced length and thickness but preserved layer structure.

Fig 1. magoo mutant cortex has reduced length and thickness but preserved layer structure.
  • Janisch KM, Vock VM, Fleming MS, Shrestha A, Grimsley-Myers CM, Rasoul BA, Neale SA, Cupp TD, Kinchen JM, Liem KF Jr, Dwyer ND

  • Development. 2013 Dec;140(23):4672-82.

2013-12-13

Fig 1. MEMRI demonstrates variable defects in the Gbx2-CKO mouse brain.

Fig 1. MEMRI demonstrates variable defects in the Gbx2-CKO mouse brain.
  • Szulc KU, Nieman BJ, Houston EJ, Bartelle BB, Lerch JP, Joyner AL, Turnbull DH

  • Magn Reson Med. 2013 Dec;70(6):1707-17.

2013-12-16

Fig 1. Chronic diseases/late effects (percent). Endo endocrine.

Fig 1. Chronic diseases/late effects (percent). Endo endocrine.
  • Ford JS, Chou JF, Sklar CA

  • J Cancer Surviv. 2013 Dec;7(4):535-43.

2013-12-17

Fig 1. Anatomic limits of pelvic lymph node dissection (PLND).

Fig 1. Anatomic limits of pelvic lymph node dissection (PLND).
  • Ploussard G, Briganti A, de la Taille A, Haese A, Heidenreich A, Menon M, Sulser T, Tewari AK, Eastham JA

  • Eur Urol. 2014 Jan;65(1):7-16.

2013-12-18

Fig 1. Single-agent activity of brentuximab vedotin in comparison with other investigational agents in patients with relapsed Hodgkin lymphoma. CR, complete remission; PR, partial remission.

Fig 1. Single-agent activity of brentuximab vedotin in comparison with other investigational agents in patients with relapsed Hodgkin lymphoma. CR, complete remission; PR, partial remission.
  • Younes A

  • Hematol Oncol Clin North Am. 2014 Feb;28(1):27-32.

2013-12-19

EμTEL-JAK2 Expression Is Associated with Elevated RNA and Protein Levels of Bcl-2, Bcl-x, and Bim.

EμTEL-JAK2 Expression Is Associated with Elevated RNA and Protein Levels of Bcl-2, Bcl-x, and Bim.
  • Waibel M, Solomon VS, Knight DA, Ralli RA, Kim SK, Banks KM, Vidacs E, Virely C, Sia KC, Bracken LS, Collins-Underwood R, Drenberg C, Ramsey LB, Meyer SC, Takiguchi M, Dickins RA, Levine R, Ghysdael J, Dawson MA, Lock RB, Mullighan CG, Johnstone RW

  • Cell Rep. 2013 Nov 20. pii: S2211-1247(13)00637-2.
Open Access button

2013-12-20

Fig 1. Kaplan-Meier curve for probability of overall survival in patients with node-positive disease.

Fig 1. Kaplan-Meier curve for probability of overall survival in patients with node-positive disease.
  • Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA

  • Eur Urol. 2014 Jan;65(1):20-5.

2013-12-23

Trends in the use of female incontinence procedures among certifying urologists between 2003 and 2012.

Trends in the use of female incontinence procedures among certifying urologists between 2003 and 2012.
  • Chughtai BI, Elterman DS, Vertosick E, Maschino A, Eastham JA, Sandhu JS

  • Urology. 2013 Dec;82(6):1267-71.

2013-12-24

Fig 1. Kaplan-Meier Analysis of Progression-Free Survival (PFS) in Patients With Advanced Breast Cancer who Were (A) < 70 Years of age and (B) ≥ 70 Years of age.
Abbreviations: CI = confidence interval; EVE = everolimus; EXE = exemestane; HR = hazard ratio; PBO = placebo.

Fig 1. Kaplan-Meier Analysis of Progression-Free Survival (PFS) in Patients With Advanced Breast Cancer who Were (A) < 70 Years of age and (B) ≥ 70 Years of age. Abbreviations: CI = confidence interval; EVE = everolimus; EXE = exemestane; HR = hazard ratio; PBO = placebo.
  • Pritchard KI, Burris HA 3rd, Ito Y, Rugo HS, Dakhil S, Hortobagyi GN, Campone M, Csöszi T, Baselga J, Puttawibul P, Piccart M, Heng D, Noguchi S, Srimuninnimit V, Bourgeois H, Gonzalez Martin A, Osborne K, Panneerselvam A, Taran T, Sahmoud T, Gnant M

  • Clin Breast Cancer. 2013 Dec;13(6):421-432.

2013-12-26

Fig 5. Model for phagosome and entotic vacuole fission.

Fig 5. Model for phagosome and entotic vacuole fission.
  • Krajcovic M, Krishna S, Akkari L, Joyce JA, Overholtzer M

  • Mol Biol Cell. 2013 Dec;24(23):3736-45.

2013-12-27

Fig 4. HDAC4 knock-down does not rescue global transcriptional dysregulation. (B) Taqman qPCR validation of the genes that were predicted to be differentially expressed between R6/2 and Dble::R6/2 cortex at 9 wk of age. See Table S3 for gene abbreviation definitions.

Fig 4. HDAC4 knock-down does not rescue global transcriptional dysregulation. (B) Taqman qPCR validation of the genes that were predicted to be differentially expressed between R6/2 and Dble::R6/2 cortex at 9 wk of age. See Table S3 for gene abbreviation definitions.
  • Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, Wanker EE, Olson EN, Luthi-Carter R, van der Putten H, Beaumont V, Bates GP

  • PLoS Biol. 2013 Nov;11(11):e1001717.
Open Access button

2013-12-30

Fig 1. Overall Survival and Progression-Free Survival in All Patients.

Fig 1. Overall Survival and Progression-Free Survival in All Patients.
  • Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, Zelenetz A, Matasar MJ, Sauter C, Goldberg J, Horwitz SM

  • Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):664-70.

2013-12-31

Fig 1. A, Kaplan-Meier OS analysis stratified by the 1988 FIGO stage 1 system (P < 0.001). B, Kaplan-Meier OS analysis stratified by the 2009 FIGO stage 1 system (P < 0.001).

Fig 1. A, Kaplan-Meier OS analysis stratified by the 1988 FIGO stage 1 system (P < 0.001). B, Kaplan-Meier OS analysis stratified by the 2009 FIGO stage 1 system (P < 0.001).
  • Barlin JN, Soslow RA, Lutz M, Zhou QC, St Clair CM, Leitao MM Jr, Iasonos A, Hensley ML, Barakat RR, Matias-Guiu X, Abu-Rustum NR

  • Int J Gynecol Cancer. 2013 Nov;23(9):1620-8.